Literature DB >> 25545322

Folate-decorated hydrophilic three-arm star-block terpolymer as a novel nanovehicle for targeted co-delivery of doxorubicin and Bcl-2 siRNA in breast cancer therapy.

Junmin Qian1, Minghui Xu1, Aili Suo2, Weijun Xu1, Ting Liu1, Xuefeng Liu1, Yu Yao3, Hongjie Wang1.   

Abstract

To minimize the side effects and enhance the efficiency of chemotherapy, a novel folate-decorated hydrophilic cationic star-block terpolymer, [poly(l-glutamic acid γ-hydrazide)-b-poly(N,N-dimethylaminopropyl methacrylamide)]3-g-poly(ethylene glycol) ((PGAH-b-PDMAPMA)3-g-PEG), with disulfide linkages between the PEG and PDMAPMA blocks, was developed for targeted co-delivery of doxorubicin and Bcl-2 small interfering RNA (siRNA) into breast cancer cells. The terpolymer was synthesized by a combination of ring-opening polymerization, reversible addition-fragmentation chain transfer polymerization, PEGylation and hydrazinolysis. The chemical structures of the polymers were confirmed by (1)H-NMR analysis. The terpolymer could conjugate doxorubicin via an acid-labile hydrazone linkage and simultaneously efficiently complex siRNA through electrostatic interaction at N/P ratios of ⩾4:1 to form "two-in-one" nanomicelleplexes, which displayed a spherical shape and had an average size of 101.3 nm. The doxorubicin loading efficiency and content were 61.0 and 13.23%, respectively. The cytotoxicity, drug release profile, targeting ability, cellular uptake and intracellular distribution of the nanomicelleplexes were evaluated in vitro. We found that the release behaviors of doxorubicin and siRNA had a pH/reduction dual dependency. They were released faster under reductive acidic conditions (pH 5.0, glutathione: 10mM) than under physiological conditions (pH 7.4). The folate-decorated nanomicelleplexes could deliver doxorubicin and Bcl-2 siRNA more efficiently into the same MCF-7 cell and exhibited a higher cytotoxicity than non-targeted nanomicelleplexes. These results indicate that the terpolymer could act as an efficient vehicle for targeted intracellular co-delivery of doxorubicin and therapeutic siRNA in cancer therapy.
Copyright © 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bcl-2 siRNA; Doxorubicin; Nanomicelleplex; Star-block terpolymer; Targeted co-delivery

Mesh:

Substances:

Year:  2014        PMID: 25545322     DOI: 10.1016/j.actbio.2014.12.018

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  10 in total

1.  Co-delivery of curcumin and Bcl-2 siRNA by PAMAM dendrimers for enhancement of the therapeutic efficacy in HeLa cancer cells.

Authors:  Maryam Ghaffari; Gholamreza Dehghan; Behzad Baradaran; Amir Zarebkohan; Behzad Mansoori; Jafar Soleymani; Jafar Ezzati Nazhad Dolatabadi; Michael R Hamblin
Journal:  Colloids Surf B Biointerfaces       Date:  2019-12-27       Impact factor: 5.268

2.  D-α-tocopherol polyethylene glycol 1000 succinate-modified liposomes with an siRNA corona confer enhanced cellular uptake and targeted delivery of doxorubicin via tumor priming.

Authors:  Xi Tan; Yan Fang; Yuanyuan Ren; Yinghuan Li; Peicheng Wu; Xiangliang Yang; Wei Liu
Journal:  Int J Nanomedicine       Date:  2019-02-18

3.  Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect via Multi-functional Nanoparticles for Orthotopic Non-Small Cell Lung Cancer Treatment.

Authors:  Fang Li; Yu Wang; Wei-Liang Chen; Dan-Dan Wang; Ye-Juan Zhou; Ben-Gang You; Yang Liu; Chen-Xi Qu; Shu-di Yang; Meng-Tian Chen; Xue-Nong Zhang
Journal:  Theranostics       Date:  2019-08-12       Impact factor: 11.556

Review 4.  Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.

Authors:  Vrinda Gote; Anantha Ram Nookala; Pradeep Kumar Bolla; Dhananjay Pal
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

5.  Co-delivery of doxorubicin and shRNA of Beclin1 by folate receptor targeted pullulan-based multifunctional nanomicelles for combinational cancer therapy.

Authors:  Lili Chen; Ming Qian; Liuwei Zhang; Jing Xia; Yongming Bao; Jingyun Wang; Lianying Guo; Yachen Li
Journal:  RSC Adv       Date:  2018-05-15       Impact factor: 4.036

Review 6.  Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.

Authors:  Shizhu Chen; Keni Yang; Ruslan G Tuguntaev; Anbu Mozhi; Jinchao Zhang; Paul C Wang; Xing-Jie Liang
Journal:  Nanomedicine       Date:  2015-12-17       Impact factor: 5.307

7.  Evaluation of the potential of a simplified co-delivery system with oligodeoxynucleotides as a drug carrier for enhanced antitumor effect.

Authors:  Chunxi Liu; Tingxian Liu; Yongjun Liu; Na Zhang
Journal:  Int J Nanomedicine       Date:  2018-04-20

Review 8.  Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery.

Authors:  Magdalena Jurczyk; Katarzyna Jelonek; Monika Musiał-Kulik; Artur Beberok; Dorota Wrześniok; Janusz Kasperczyk
Journal:  Pharmaceutics       Date:  2021-03-03       Impact factor: 6.321

Review 9.  Receptor-Mediated Targeted Delivery of Surface-ModifiedNanomedicine in Breast Cancer: Recent Update and Challenges.

Authors:  Md Rizwanullah; Mohammad Zaki Ahmad; Mohammed M Ghoneim; Sultan Alshehri; Syed Sarim Imam; Shadab Md; Nabil A Alhakamy; Keerti Jain; Javed Ahmad
Journal:  Pharmaceutics       Date:  2021-11-29       Impact factor: 6.321

10.  An "eat me" combinatory nano-formulation for systemic immunotherapy of solid tumors.

Authors:  Hend Mohamed Abdel-Bar; Adam A Walters; Yau Lim; Nadia Rouatbi; Yue Qin; Fatemeh Gheidari; Shunping Han; Rihab Osman; Julie Tzu-Wen Wang; Khuloud T Al-Jamal
Journal:  Theranostics       Date:  2021-08-11       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.